Advertisement

Topics

Supreme Court overturns the Federal Circuit, granting more flexibility to biosimilar makers

23:35 EDT 21 Jun 2017 | Topix

In a unanimous opinion, the United States Supreme Court again reversed the Federal Circuit in Sandoz Inc. v. Amgen Inc. , interpreting the meaning of key provisions of the Biologics Price Competition and Innovation Act of 2009.

Original Article: Supreme Court overturns the Federal Circuit, granting more flexibility to biosimilar makers

NEXT ARTICLE

More From BioPortfolio on "Supreme Court overturns the Federal Circuit, granting more flexibility to biosimilar makers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...